

## ASX ANNOUNCEMENT

### Analytica Announces Grant of US Patent for PeriCoach

**30 April 2021.** Analytica Ltd (ASX:ALT), manufacturer of the PeriCoach® pelvic floor exercise system is pleased to announce the granting of US patent 10,966,654<sup>1</sup> "Intra vaginal device to aid in training and determining muscle strength" concerning the use of motion sensors in pelvic floor exercise devices.

The patent was granted on 6 April 2021 and will expire on 16 October 2035 provided all renewal fees are paid.

The US is the biggest medical device market in the world and this patent gives Analytica a level of intellectual property protection in this market for the pelvic floor exercise technique features of the PeriCoach system.

The PeriCoach technique feedback functionality uses inputs from the uniquely positioned PeriCoach force sensors, whose invention is described in a separate patent family<sup>2</sup>, and movement sensors to assess the technique used to contract the pelvic floor muscles. This information is presented to the patient as she does her exercise via the PeriCoach app. Analytica's real-world data from paying patients shows that 57% of women don't engage their pelvic floor muscles correctly when they first start pelvic floor exercise. With the real-time biofeedback provided by PeriCoach, they are able to correct their contraction technique.

This invention has also been granted patent protection in Australia. Analytica also has patent protection granted for the PeriCoach force sensor orientation in Australia, China and Japan. Both patent families have applications pending in other jurisdictions such as Europe.

*Authorised for release by the Board*

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

#### About Analytica Limited

Analytica is a product development and commercialisation company, based in Queensland, Australia, focussed on Class I and II medical device products.

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in



<sup>1</sup> <https://patents.google.com/patent/US10966654B2>

<sup>2</sup> <https://patents.google.com/patent/WO2012142646A1>



pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia and has CE mark and USFDA 510(k) clearance for the treatment of urinary incontinence.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of mild to moderate pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

Analytica is also the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to reduce nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.